← Eichor
Condition: Relapsed Refractory Idiopathic Inflammatory Myopathies Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsed Refractory Idiopathic Inflammatory Myopathies

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT06980597CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06614270AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Stud
Phase 2 · 52 location(s) · Artiva Biotherapeutics, Inc. · NCT06991114A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflamm
Phase 1 · 5 location(s) · Nanjing Legend Biotech Co. · NCT07331272A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · CytoCares Inc · NCT07193810An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT07174843Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous Sys
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT04561557Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media
Phase 1 · 1 location(s) · Tongji Hospital · NCT07526493Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06350110Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07361094
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.